|Bid||38.16 x 200|
|Ask||70.00 x 100|
|Day's Range||52.64 - 54.92|
|52 Week Range||15.68 - 67.10|
|PE Ratio (TTM)||-12.42|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||65.37|
FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.
Research Desk Line-up: Alnylam Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Portola ...
Categories: Yahoo FinanceGet free summary analysis Portola Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Portola Pharmaceuticals, Inc. – Johnson & Johnson, Biogen Inc., Bristol-Myers Squibb Company, Pfizer Inc. and Sanofi Sponsored ADR (JNJ-US, BIIB-US, BMY-US, PFE-US and SNY-US) that have also reported ... Read more (Read more...)